Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy
暂无分享,去创建一个
Constantino Carlos Reyes-Aldasoro | Jakob Nikolas Kather | Rodrigo Rojas-Moraleda | Niels Halama | Dirk Jäger | Anna Sophie Berghoff | Dyke Ferber | Meggy Suarez-Carmona | Nektarios A. Valous | N. Halama | D. Jäger | C. Reyes-Aldasoro | N. Valous | M. Suarez-Carmona | Rodrigo Rojas-Moraleda | A. Berghoff | D. Ferber
[1] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[2] Soumen Roy,et al. Microbiota: a key orchestrator of cancer therapy , 2017, Nature Reviews Cancer.
[3] M. Wallack,et al. Immunotherapy in colorectal cancer. , 1981, Missouri medicine.
[4] E. Jaffee,et al. Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.
[5] Simone Fulda,et al. Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.
[6] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[7] Thomas Davis,et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Teresa Villanueva. Immunotherapy: T cells get a ride , 2017, Nature Reviews Cancer.
[9] Daniel Andersson,et al. Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts , 2017, Molecular Cancer.
[10] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[11] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[13] S. Rosenberg,et al. A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.
[14] E. Chiocca,et al. Oncolytic Viruses in Cancer Treatment: A Review , 2017, JAMA oncology.
[15] Constantino Carlos Reyes-Aldasoro,et al. The proportion of cancer-related entries in PubMed has increased considerably; is cancer truly “The Emperor of All Maladies”? , 2017, PloS one.
[16] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] Michel Sadelain,et al. Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.
[18] S. Woolf. The meaning of translational research and why it matters. , 2008, JAMA.
[19] M. Pittet,et al. The role of myeloid cells in cancer therapies , 2016, Nature Reviews Cancer.
[20] L. Gammaitoni,et al. Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective , 2014, Expert opinion on biological therapy.
[21] Yiping Yang,et al. Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.
[22] Axel Hoos,et al. Classification of current anticancer immunotherapies , 2014, Oncotarget.
[23] Virapong Prachayasittikul,et al. Exploring the epigenetic drug discovery landscape , 2017, Expert opinion on drug discovery.
[24] Cynthia A. Brewer,et al. ColorBrewer.org: An Online Tool for Selecting Colour Schemes for Maps , 2003 .
[25] T. Blankenstein,et al. Immunotherapy: target the stroma to hit the tumor. , 2005, Trends in molecular medicine.
[26] A. Snyder,et al. Acquired resistance to immunotherapy and future challenges , 2016, Nature Reviews Cancer.
[27] Hongming Pan,et al. Autophagy-associated immune responses and cancer immunotherapy , 2016, Oncotarget.
[28] Antoni Ribas,et al. Current developments in cancer vaccines and cellular immunotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Tak W. Mak,et al. The current state of cancer metabolism , 2016, Nature Reviews Cancer.
[30] J. Wolchok,et al. Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.